Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) have earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $88.80.
ALXO has been the topic of several research reports. UBS Group began coverage on shares of ALX Oncology in a report on Tuesday, April 6th. They set a “buy” rating and a $96.00 price objective on the stock. Credit Suisse Group started coverage on ALX Oncology in a report on Wednesday, May 5th. They set an “outperform” rating and a $98.00 price objective for the company. HC Wainwright reiterated a “buy” rating on shares of ALX Oncology in a report on Wednesday, July 7th. Finally, Zacks Investment Research lowered shares of ALX Oncology from a “buy” rating to a “hold” rating in a research note on Tuesday.
ALX Oncology stock traded up $2.28 during trading hours on Thursday, reaching $60.66. 6,410 shares of the company’s stock were exchanged, compared to its average volume of 222,517. The stock’s 50 day moving average price is $56.23. ALX Oncology has a twelve month low of $28.01 and a twelve month high of $117.45.
In other news, CEO Jaume Pons sold 16,700 shares of the firm’s stock in a transaction on Monday, July 19th. The stock was sold at an average price of $54.57, for a total transaction of $911,319.00. Following the completion of the sale, the chief executive officer now directly owns 509,946 shares of the company’s stock, valued at approximately $27,827,753.22. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Sophia Randolph sold 7,387 shares of the business’s stock in a transaction dated Monday, July 12th. The stock was sold at an average price of $54.90, for a total transaction of $405,546.30. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 57,487 shares of company stock worth $3,225,675. 58.20% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of ALX Oncology in the first quarter valued at $49,000. Penserra Capital Management LLC purchased a new position in shares of ALX Oncology in the fourth quarter valued at $73,000. Pacer Advisors Inc. raised its stake in shares of ALX Oncology by 126.5% during the 1st quarter. Pacer Advisors Inc. now owns 1,010 shares of the company’s stock valued at $74,000 after purchasing an additional 564 shares during the period. First Mercantile Trust Co. lifted its holdings in ALX Oncology by 16.1% during the 1st quarter. First Mercantile Trust Co. now owns 1,404 shares of the company’s stock worth $104,000 after purchasing an additional 195 shares in the last quarter. Finally, E Fund Management Co. Ltd. purchased a new stake in ALX Oncology in the first quarter valued at approximately $133,000. 83.30% of the stock is owned by institutional investors and hedge funds.
About ALX Oncology
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer.
Further Reading: Why do commodities matter?
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.